Effectiveness of an add-on treatment with the homeopathic medication SilAtro-5-90 in recurrent tonsillitis: An international, pragmatic, randomized, controlled clinical trial

التفاصيل البيبلوغرافية
العنوان: Effectiveness of an add-on treatment with the homeopathic medication SilAtro-5-90 in recurrent tonsillitis: An international, pragmatic, randomized, controlled clinical trial
المؤلفون: Karin Wienhold, Stephan Weber, Joaquin Perotti Fernández, Sergiy Michailovich Pukhlik, Kira Kompaniiets, Inga Mityuryayeva-Korniiko, Jürgen Palm, Anatolii Kosakovskyi, Miek C. Jong, Petra Klement, Zoia Tretiakevych, Àngels Ulied, Vasyl Kishchuk, Thomas Keller, Sabine De Jaegere
المصدر: Complementary therapies in clinical practice. 28
سنة النشر: 2017
مصطلحات موضوعية: SilAtro-5-90, Adult, Male, medicine.medical_specialty, Adolescent, medicine.drug_class, Recurrent tonsillitis, Antibiotics, Nursing, law.invention, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Randomized controlled trial, law, Recurrence, Internal medicine, Throat, medicine, Humans, 030212 general & internal medicine, Child, business.industry, Omvårdnad, Standard treatment, Communication, Hazard ratio, Pharyngitis, Homeopathy, Middle Aged, 030205 complementary & alternative medicine, Anti-Bacterial Agents, Clinical trial, Tonsillitis, medicine.anatomical_structure, Treatment Outcome, Complementary and alternative medicine, Materia Medica, Physical therapy, Acute throat infection, Female, business, Tonsilotren
الوصف: Objective To investigate the effectiveness and safety of the homeopathic product SilAtro-5-90 in recurrent tonsillitis. Methods In this international, pragmatic, controlled clinical trial, 256 patients (6–60 years) with moderate recurrent tonsillitis were randomized to receive either SilAtro-5-90 in addition to standard symptomatic treatment, or to receive standard treatment only. The primary outcome was the mean time period between consecutive acute throat infections (ATI) within 1 year (analyzed via repeated events analysis). Results During the evaluation year, the risk of getting an ATI was significantly lower (hazard ratio: 0.45, proportional means model, p = 0.0002, ITT ) with SilAtro-5-90 compared to control. Tonsillitis-specific symptoms were significantly reduced ( p 0.0001, ITT ) and the need of antibiotics to treat acute throat infections ( p = 0.0008; ITT ) decreased. 3 non-serious adverse drug reactions were reported for SilAtro-5-90. Conclusions An integrative treatment approach where SilAtro-5-90 is given alongside mainstream symptomatic treatment may bring therapeutic benefit to patients suffering from recurrent tonsillitis. Trial registration: ISRCTN registry: Registration number ISRCTN19016626, registered 23 January 2013.
وصف الملف: application/pdf
تدمد: 1873-6947
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9776ac8d8c9facb1798fcade04624e
https://pubmed.ncbi.nlm.nih.gov/28779928
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....6d9776ac8d8c9facb1798fcade04624e
قاعدة البيانات: OpenAIRE